The story of Sildenafil presents a challenging picture for investors. While the initial introduction generated substantial profits, the end of its exclusive rights opened the door to off-brand versions, dramatically reducing revenue. This presents a particular risk for firms relying on similar blockbuster products, suggesting that a unquestioning i

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in income, its patent expiration created a flood of lower-priced alternatives , significantly eroding its market share . While certain firms may try to capitalize on related treatments , the current land